Stos leczenia
Synergistic tissue repair — BPC-157 targets gut and tendon via mTOR and NO pathways; TB-500 promotes systemic repair and angiogenesis. Research suggests complementary mechanisms with non-overlapping targets.
Uzasadnienie →Kombinacje związków z udokumentowanym uzasadnieniem mechanistycznym
Synergistic tissue repair — BPC-157 targets gut and tendon via mTOR and NO pathways; TB-500 promotes systemic repair and angiogenesis. Research suggests complementary mechanisms with non-overlapping targets.
Uzasadnienie →Skin-focused combination — GHK-Cu stimulates collagen and antioxidant pathways; BPC-157 supports wound healing and tissue repair. Often explored for skin rejuvenation in anecdotal literature.
Uzasadnienie →CJC-1295 (GHRH analogue) and Ipamorelin (GHRP/ghrelin agonist) act on different points of the GH axis, producing synergistic pulsatile GH release while minimizing cortisol/prolactin side effects associated with older GHRPs.
Uzasadnienie →Więcej stacków — w tym kombinacje bioregulatorów i nootropików — wkrótce.